HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches - sprookjes - yvandenbroek - TriplyDB

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

http://www.wikidata.org/entity/Q26866534

about

Targeted therapies and immunotherapy in non-small-cell lung cancer Lung cancer biomarkers, targeted therapies and clinical assays Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors Recent advances in personalized lung cancer medicine KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer.HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.Targeted therapy for leptomeningeal metastases in non-small cell lung cancer - Changing treatment paradigms.Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.Hierarchical closeness-based properties reveal cancer survivability and biomarker genes in molecular signaling networks.

P2860

Q26738986-1DB53D1A-D719-4DC6-BE1A-639318609753 Q26775396-54B6A887-8AB7-45F9-943A-0BA247D1C139 Q28080730-07F90F4C-86D4-4E98-B11B-7CCC61E483E9 Q28086768-220BA05D-85D0-4A99-9D0A-220743D69E2A Q34678073-D38D6DF7-0366-474C-940E-BB14B0C03E33 Q37353957-839306CB-5348-4C19-82CB-1964CFBFE189 Q37582387-8413DA09-D78E-4D0C-89F6-19A40EC17129 Q37667783-6D3A876A-3BFF-42A5-9AC8-A357ED377985 Q37688390-EB69294E-65E7-4318-9AC0-F61B5FB89201 Q38704805-8B04E98F-B819-4823-A9D6-E8EB4E9A55A0 Q49894049-D117F156-13FE-4F94-9614-64585CC7DA21 Q50026716-D5224ABC-F82F-4338-9095-514EA7A4C75D Q55242072-2626DC7E-1FE9-4EAE-8BFC-668E4685F0F1

P2860

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

http://www.wikidata.org/entity/Q26866534

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

@ast

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

@en

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

@nl

type

label

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

@ast

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

@en

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

@nl

prefLabel

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

@ast

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

@en

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

@nl

P1433

Q26866534-9C756E10-7FEB-4028-8AA7-9130339378BD

P1476

Q26866534-03C22369-91AA-4608-A0AF-9801781689A1

P2093

Q26866534-B0DCDDEE-521F-4388-9B18-492E634C0CEA

P2860

Q26866534-09E6B83F-05F7-4CBE-A451-F0ADE7E50192

Q26866534-21136DA5-0D7A-4860-B714-763B9C810CD9

Q26866534-27DA5A05-98C7-4A15-B5FF-245D3FE0D09D

Q26866534-3909C8AB-7B03-4F4E-8E96-BBF5837CD0A7

Q26866534-40E4FAF9-E63E-42BF-9BF5-B6DF5BF23E2D

Q26866534-66220201-D452-4BAE-A2C7-C179AF1A46EB

Q26866534-7AA8E12F-FE3E-4BDF-899A-95B8D5EE7047

Q26866534-7CDF514C-0C0B-4AF7-9AD0-080E4EF1F2A7

Q26866534-7CFD57A8-4019-438B-A66E-7F7DB37DB9E5

Q26866534-8FE7A69F-5D2D-4078-BDD5-362E77E48B07

P304

Q26866534-91E9EBB4-18FB-45BD-9BE3-04913A8157ED

P31

Q26866534-17B44142-EF19-4A20-A2FA-56446DA5B73F

P3181

Q26866534-DA04438D-705A-42F6-8A26-54CF37072FB9

P356

Q26866534-CB2D8240-7D3B-4E3D-8529-2348935276CF

P407

Q26866534-D5869803-A645-4D37-ABEC-CFC1F4A4F79E

P433

Q26866534-E737EB43-D9E9-4C3E-A9FF-A2A3ED887478

P478

Q26866534-BD0A1183-2B04-439F-BB98-C8B6BD2B7888

P50

Q26866534-7DAC051F-73D2-4BB4-86A3-266E9BD63064

P577

Q26866534-7416E02F-4316-4C9F-B574-48AFAB94657F

P698

Q26866534-E7A32F94-543C-418C-84E3-B030B70264C2

P932

Q26866534-3A427AF3-0FB3-49B3-BE50-82AE8986133E

P3181

P356

J.ISSN.2218-6751.2013.02.02

P1433

Translational lung cancer research

P1476

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

@en

P2093

Ana Christina Garrido-Castro

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Cancer statistics, 2012

Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers

P304

122-127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

560040

http://www.w3.org/2001/XMLSchema#string

P356

10.3978/J.ISSN.2218-6751.2013.02.02

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Enriqueta Felip

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25806223

http://www.w3.org/2001/XMLSchema#string

P932

4369854

http://www.w3.org/2001/XMLSchema#string